Johnson & Johnson (NYSE:JNJ) will be issuing its quarterly earnings data before the market opens on Tuesday, January 23rd. Analysts expect the company to announce earnings of $1.72 per share for the quarter.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, October 17th. The company reported $1.90 EPS for the quarter, topping analysts’ consensus estimates of $1.80 by $0.10. Johnson & Johnson had a return on equity of 27.38% and a net margin of 21.28%. The company had revenue of $19.65 billion during the quarter, compared to analyst estimates of $19.29 billion. During the same quarter last year, the firm posted $1.68 earnings per share. The firm’s revenue was up 10.3% on a year-over-year basis. On average, analysts expect Johnson & Johnson to post $7 EPS for the current fiscal year and $8 EPS for the next fiscal year.

Shares of Johnson & Johnson (JNJ) opened at $145.76 on Tuesday. Johnson & Johnson has a 52 week low of $110.76 and a 52 week high of $146.42. The company has a market capitalization of $391,590.00, a price-to-earnings ratio of 25.31, a P/E/G ratio of 2.75 and a beta of 0.80. The company has a quick ratio of 1.02, a current ratio of 1.32 and a debt-to-equity ratio of 0.36.

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 13th. Investors of record on Tuesday, February 27th will be paid a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a yield of 2.31%. The ex-dividend date of this dividend is Monday, February 26th. Johnson & Johnson’s payout ratio is 58.33%.

A number of brokerages recently commented on JNJ. Piper Jaffray Companies reaffirmed a “hold” rating and issued a $120.00 price target on shares of Johnson & Johnson in a research note on Wednesday, October 4th. Vetr lowered Johnson & Johnson from a “hold” rating to a “sell” rating and set a $130.49 price target for the company. in a research note on Monday, September 18th. Stifel Nicolaus raised their price target on Johnson & Johnson from $140.00 to $142.00 and gave the stock a “hold” rating in a research note on Wednesday, October 18th. Wells Fargo & Co raised Johnson & Johnson from a “market perform” rating to an “outperform” rating and raised their price target for the stock from $140.00 to $149.00 in a research note on Monday, October 9th. Finally, JPMorgan Chase & Co. lowered Johnson & Johnson from an “overweight” rating to a “neutral” rating in a research note on Tuesday, January 2nd. Four investment analysts have rated the stock with a sell rating, seven have given a hold rating and eleven have given a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $145.94.

A number of institutional investors have recently made changes to their positions in JNJ. Harding Loevner LP purchased a new position in Johnson & Johnson during the second quarter valued at $106,000. IHT Wealth Management LLC lifted its position in Johnson & Johnson by 46.4% during the second quarter. IHT Wealth Management LLC now owns 10,942 shares of the company’s stock valued at $122,000 after buying an additional 3,467 shares during the period. Mountain Capital Investment Advisors Inc purchased a new position in Johnson & Johnson during the second quarter valued at $124,000. Lenox Wealth Management Inc. lifted its position in Johnson & Johnson by 1.7% during the second quarter. Lenox Wealth Management Inc. now owns 1,457 shares of the company’s stock valued at $193,000 after buying an additional 24 shares during the period. Finally, Intercontinental Wealth Advisors LLC purchased a new position in Johnson & Johnson during the second quarter valued at $200,000. 65.71% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This story was posted by American Banking News and is owned by of American Banking News. If you are viewing this story on another publication, it was illegally stolen and republished in violation of U.S. & international trademark & copyright law. The correct version of this story can be viewed at https://www.americanbankingnews.com/2018/01/16/johnson-johnson-jnj-scheduled-to-post-quarterly-earnings-on-tuesday.html.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Earnings History for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.